Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Castle BiosciencesCSTL +5.12%80 12-1 Month Momentum % is 21.27% as of Aug. 10, 2026. GuruFocus rates CSTL with a GF Score™ of 80/100 and a GF Value™ of $29.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Castle Biosciences ranks better than 72.77% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-10), Castle Biosciences's 12-1 Month Momentum % is 21.27%.
The industry rank for Castle Biosciences's 12-1 Month Momentum % or its related term are showing as below:
CSTL's 12-1 Month Momentum % is ranked better than 72.77% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -7.06
vs CSTL: 21.27
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Castle Biosciences 12-1 Month Momentum % Related Terms
CSTL vs OPK, FLGT, MYGN: 12-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences 12-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a 12-1 Month Momentum % of 21.27% as of Aug. 10, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #58 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 27.2%.
Is Castle Biosciences' 12-1 Month Momentum % too high?
Castle Biosciences' current 12-1 Month Momentum % is 21.27%. Based on the distribution chart, Castle Biosciences ranks #58 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' 12-1 Month Momentum % compare to OPK and FLGT?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #58 out of 213 companies for 12-1 Month Momentum %. This puts Castle Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current 12-1 Month Momentum % is 21.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Fairly Valued. The stock's GF Value™ is $29.71, compared to a current price of $32.01 — trading 7.7% above its estimated fair value. The current 12-1 Month Momentum % is 21.27%. Castle Biosciences' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current 12-1 Month Momentum % is 21.27% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued.
The current stock price of $32.01 is trading 7.7% above its estimated GF Value™ of $29.71.
GuruFocus considers Castle Biosciences to be Fairly Valued.
Key valuation signals for CSTL:
12-1 Month Momentum %: 21.27%
GF Value™: $29.71 vs. price of $32.01 (7.7% above fair value)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
80GF Score
Get the complete analysis for CSTL
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
